Welcome to our dedicated page for Eledon Pharmaceuticals SEC filings (Ticker: ELDN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Eledon Pharmaceuticals, Inc. (ELDN) SEC filings page provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Eledon is a clinical stage biotechnology company focused on immune-modulating therapies built around the CD40 Ligand (CD40L) pathway, with its common stock listed on the Nasdaq Capital Market under the symbol ELDN, as noted in its Form 8-K filings.
Through this page, readers can review key documents such as annual reports on Form 10-K and quarterly reports on Form 10-Q, which describe Eledon’s clinical programs for its lead investigational product tegoprubart, risk factors, and financial position. Current reports on Form 8-K provide more targeted updates, including material events related to clinical data disclosures, financing transactions and other significant corporate developments.
For example, an 8-K dated November 12, 2025 outlines an underwriting agreement for an underwritten public offering of common stock and pre-funded warrants, including the intended use of net proceeds to support continued clinical development and pipeline advancement. Other 8-K filings describe preliminary cash, cash equivalents and short-term investment balances, as well as press releases announcing Phase 2 BESTOW trial results and updated data from a Phase 1b kidney transplant study.
On Stock Titan, these filings are supplemented by AI-powered summaries that explain the main points of lengthy documents, helping users quickly understand topics such as capital raises, clinical trial disclosures and selected financial information. Real-time updates from EDGAR allow timely viewing of new ELDN filings, while access to forms like 10-K, 10-Q and 8-K supports deeper analysis of Eledon’s clinical-stage operations, financing activities and risk disclosures.
Eledon Pharmaceuticals, Inc. received an amended Schedule 13G from RA Capital Management and related reporting persons regarding its common stock. As of December 31, 2025, RA Capital Management, Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. each report beneficial ownership of 0 shares and 0.0% of the common stock, with no sole or shared voting or dispositive power. The filers also certify that the securities referenced were not acquired and are not held for the purpose of changing or influencing control of Eledon Pharmaceuticals.
Coastlands-affiliated funds and Matthew D. Perry report minority ownership in Eledon Pharmaceuticals, Inc. on an amended Schedule 13G. Coastlands Capital LP, Coastlands Capital Partners LP, Coastlands Capital GP LLC, Coastlands Capital LLC and Perry collectively report beneficial ownership of 3,937,826 shares of Eledon common stock, representing 4.99% of the class.
This position includes 450,000 shares held directly by Coastlands Capital LP and 3,487,826 shares issuable upon exercise of pre-funded warrants, all subject to a 4.99% beneficial ownership limitation. Perry’s reported beneficial ownership of 3,908,467 shares includes additional stock held through a trust. The filers state the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of Eledon.
BlackRock, Inc. has filed an amended ownership report showing that it beneficially owns 3,625,824 shares of Eledon Pharmaceuticals, Inc. common stock, representing 4.6% of the outstanding class as of the event date. BlackRock reports sole voting power over 3,584,479 shares and sole dispositive power over 3,625,824 shares, with no shared voting or dispositive power.
The filing states that these securities are held by certain BlackRock business units in the ordinary course of business and are not held for the purpose of changing or influencing control of Eledon Pharmaceuticals. The filing also notes that various underlying clients and investors have rights to dividends or sale proceeds, but no single person has more than five percent of Eledon’s total outstanding common shares.
Eledon Pharmaceuticals director John McBride reported the vesting and settlement of restricted stock units into common shares. On January 10, 2026, 3,430 restricted stock units were converted into 3,430 shares of Eledon Pharmaceuticals common stock at a price of $0 per share. These RSUs had been granted on January 10, 2025 and vested 100% one year later. Following this transaction, McBride directly holds 3,430 shares of common stock.
Eledon Pharmaceuticals director Jan Hillson reported the vesting and settlement of 3,430 restricted stock units into 3,430 shares of common stock. The transaction occurred on January 10, 2026 through an option exercise coded "M" at a price of $0 per share. The RSUs were originally granted on January 10, 2025 and vested in full one year later, delivering common shares to the director on a one-for-one basis. Following this transaction, Hillson directly holds 3,430 shares of Eledon Pharmaceuticals common stock.
Eledon Pharmaceuticals director Allan Kirk reported acquiring common shares through the vesting of equity awards. On January 10, 2026, 3,430 restricted stock units (RSUs) that had been granted on January 10, 2025 vested in full and were settled into 3,430 shares of Eledon Pharmaceuticals common stock on a one-for-one basis.
The RSU settlement was reported at a price of $0 per share, reflecting that no cash was paid in this conversion. Following the transaction, Allan Kirk beneficially owned 3,430 shares of common stock directly.
Eledon Pharmaceuticals director Keith Katkin reported the vesting and settlement of restricted stock units into common shares. On January 10, 2026, 8,575 restricted stock units converted into 8,575 shares of Eledon Pharmaceuticals common stock at a price of $0 per share, reflected as a transaction coded "M". These RSUs were originally granted on January 10, 2025 and vested 100% on January 10, 2026. Following the transaction, Katkin beneficially owned 8,575 shares of common stock directly.
Eledon Pharmaceuticals director June Lee reported the vesting and settlement of restricted stock units into common shares. On January 10, 2026, 3,430 restricted stock units converted into 3,430 shares of common stock at a price of $0 per share, leaving Lee with 3,430 common shares held directly after the transaction.
The footnote explains that these shares came from restricted stock units granted on January 10, 2025, which vested 100% on January 10, 2026 on a one-for-one basis into common stock. Following the conversion, the derivative position in these restricted stock units was reduced to zero.
Eledon Pharmaceuticals director reports RSU vesting and share settlement. Director James A. Robinson Jr. settled 3,430 restricted stock units (RSUs) into 3,430 shares of common stock on January 10, 2026, in a transaction coded "M" at a price of $0 per share. The RSUs were originally granted on January 10, 2025 and vested 100% on January 10, 2026.
Following this settlement, Robinson directly holds 3,430 shares of Eledon Pharmaceuticals common stock. The derivative position in the RSUs reported in this filing is now shown as 0 derivative securities beneficially owned, reflecting the full conversion into common shares.
Eledon Pharmaceuticals reports a Q3 2025 net loss of $17.5 million, driven by $19.1 million of operating expenses, mainly research and development on its lead anti-CD40L antibody tegoprubart. For the first nine months of 2025, the net loss was $35.2 million on $61.8 million of operating expenses, reflecting heavier R&D investment versus 2024.
At September 30, 2025, Eledon held $3.7 million in cash and cash equivalents and $89.7 million in short-term investments, for total liquid resources of $93.4 million and working capital of $82.0 million. Management believes this is sufficient to fund planned operations for at least 12 months from the filing date, while noting that additional financing will be needed to support longer-term plans.
Warrant liabilities declined to $21.9 million from $44.9 million at year-end 2024, producing a $22.9 million non-cash gain over nine months. The company also restated prior financial statements to treat its Series X and X1 non-voting convertible preferred stock as a separate class for earnings per share and to classify it as temporary equity due to certain contingent redemption features.